Reply to: Steroids in cystic fibrosis exacerbations: are we picking the right patients?

IF 16.6 1区医学 Q1 RESPIRATORY SYSTEM

European Respiratory Journal Pub Date : 2024-10-03 DOI:10.1183/13993003.01713-2024

Valerie Waters, Bradley Quon, Felix Ratjen

引用次数: 0

Abstract

Extract

We thank D. Beinart and co-workers for their insightful comments and important question regarding the PIPE Study of oral prednisone as adjunctive therapy for pulmonary exacerbations in people with cystic fibrosis (CF) [1].

查看原文本刊更多论文

答复治疗囊性纤维化加重的类固醇：我们选对病人了吗？

摘录我们感谢 D. Beinart 及其合作者提出的富有洞察力的意见和重要问题，这些意见和问题涉及将口服泼尼松作为囊性纤维化 (CF) 患者肺部恶化的辅助疗法的 PIPE 研究 [1]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Respiratory Journal 医学-呼吸系统

CiteScore

27.50

自引率

3.30%

发文量

345

审稿时长

2-4 weeks

期刊介绍： The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.